Cambridge, UK: Intertek, a leading Total Quality Assurance provider to industries worldwide, is pleased to announce that it has entered a partnership with CrystecPharma, focusing on advancing formulation science and accelerating development timelines for inhaled medicines, particularly dry powder inhaler (DPI) products.
Crystec is delighted to be attending DDL 2024 (Drug Delivery to the Lungs) on its 35-year anniversary at Edinburgh International Conference Centre, from December 11th to December 13th.
Crystec is attending DDL 2024 in Edinburgh, UK Read More »
Crystec is thrilled to be attending the 3rd Annual Inhaled & Nasal Biologics / DNA Forum in Cambridge, UK, on September 26th and 27th!
Meet with the Crystec team at CPhI2023 in Barcelona to explore how we can transform the performance of medicines together.
Crystec at #CPhI2023 Read More »
Exciting times ahead at #BIO2023 in Boston! Join us as we bring together the brightest minds in biotechnology to discuss the latest breakthroughs and innovations. Don’t miss this opportunity to network, learn, and collaborate.
Meet Crystec at BIO2023 Read More »
We are delighted to announce that we have been shortlisted for the BioNow Technical Service of the Year Award 2022. The submission, ‘mSAS® – revolutionising the speed and efficiency of biomolecule product development’, encompasses the significant advances that we have made in this area, and are now able to routinely offer to our clients.
BioNow Technical Service of the Year Award 2022 Read More »
CrystecPharma recently attended, and presented at, the first edition of Therapeutic Area Partnerships: Accelerating Innovation in Women’s Health, a digital conference delivered by Informa Connect.
Therapeutic Area Partnerships: Accelerating Innovation in Women’s Health Read More »
19th October 2021. Crystec Ltd. and Biosidus S.A. are delighted to announce their collaboration focused on enhancing the delivery and performance of biotherapeutics.
A collaboration to enhance the delivery of biotherapeutics Read More »
